1GILD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$86.35 |
| 52 Week High | US$92.68 |
| 52 Week Low | US$58.38 |
| Beta | 0.19 |
| 11 Month Change | 4.92% |
| 3 Month Change | 26.02% |
| 1 Year Change | 24.86% |
| 33 Year Change | 38.03% |
| 5 Year Change | 41.44% |
| Change since IPO | 25.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1GILD | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 0.9% | 2.9% | -1.6% |
| 1Y | 24.9% | 5.3% | 12.4% |
Return vs Industry: 1GILD exceeded the Italian Biotechs industry which returned 5.3% over the past year.
Return vs Market: 1GILD exceeded the Italian Market which returned 12.4% over the past year.
Price Volatility
| 1GILD volatility | |
|---|---|
| 1GILD Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: 1GILD has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1GILD's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| 1GILD fundamental statistics | |
|---|---|
| Market cap | €107.94b |
| Earnings (TTM) | €121.00m |
| Revenue (TTM) | €27.18b |
892.1x
P/E Ratio4.0x
P/S RatioIs 1GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1GILD income statement (TTM) | |
|---|---|
| Revenue | US$28.30b |
| Cost of Revenue | US$6.28b |
| Gross Profit | US$22.02b |
| Other Expenses | US$21.89b |
| Earnings | US$126.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 77.80% |
| Net Profit Margin | 0.45% |
| Debt/Equity Ratio | 126.4% |
How did 1GILD perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield3,027%
Payout RatioDoes 1GILD pay a reliable dividends?
See 1GILD dividend history and benchmarks| Gilead Sciences dividend dates | |
|---|---|
| Ex Dividend Date | Dec 12 2024 |
| Dividend Pay Date | Dec 30 2024 |
| Days until Ex dividend | 17 days |
| Days until Dividend pay date | 35 days |
Does 1GILD pay a reliable dividends?
See 1GILD dividend history and benchmarks